Anti-IgE: A treatment option in allergic rhinitis?
Authors:
- Oliver PfaarOPOliver Pfaar
- Francesca GehrtFGFrancesca Gehrt
- Hansen LiHLHansen Li
- Stefan A. RudhartSRStefan A. Rudhart
- Alexander NastevANAlexander Nastev
- Boris A. StuckBSBoris A. Stuck
- Stephan HochSHStephan Hoch
- 1 January 2021
- journal article
- review article
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 5 (01) , 119-127
Abstract
Background: Allergic rhinitis (AR) is the most common IgE-mediated allergic disease. Multiple clinical trials have demonstrated promising results on the AR treatment with biologics, in particular with the use of omalizumab – an anti-IgE antibody. Omalizumab has also been established in the routine management of allergic asthma and chronic idiopathic urticaria. However, currently there is no approved license for the use of biologics in AR in Germany. Materials and methods: A systematic literature review has been completed including randomized controlled trials, meta-analyses, and reviews on the treatment of AR with omalizumab. Results: The systematic review demonstrates strong evidence supporting the use of omalizumab in the treatment of AR with regard to symptom control, safety profile, and management of comorbidities. Conclusion: Omalizumab is a good and safe option in the treatment of AR in terms of symptom control and the management of pre-existing comorbidities. Further clinical trials with other biologics in the management of AR are needed and are expected to follow soon.Keywords
This publication has 55 references indexed in Scilit:
- Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co‐morbid seasonal allergic asthmaClinical & Experimental Allergy, 2009
- Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*Allergy, 2008
- Worldwide time trends for symptoms of rhinitis and conjunctivitis: Phase III of the International Study of Asthma and Allergies in ChildhoodPediatric Allergy and Immunology, 2007
- Safety of anti‐immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infectionClinical & Experimental Allergy, 2007
- Omalizumab is Effective and Safe in the Treatment of Japanese Cedar Pollen-induced Seasonal Allergic RhinitisAllergology International, 2006
- Omalizumab rapidly decreases nasal allergic response and FcεRI on basophilsJournal of Allergy and Clinical Immunology, 2004
- Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitisAnnals of Allergy, Asthma & Immunology, 2003
- Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitisJournal of Allergy and Clinical Immunology, 2002
- Treatment of Allergic Asthma with Monoclonal Anti-IgE AntibodyNew England Journal of Medicine, 1999
- Characterization of Complex Formation by Humanized Anti-IgE Monoclonal Antibody and Monoclonal Human IgEBiochemistry, 1995